Broker recommendations for Abbott Laboratories
The Abbott Laboratories stock is rated at 1.357143 (on a scale 1-3, where 1 is ‘strong buy‘ and 3 is ‘strong sell‘) from Wednesday 9 September, 2020 by a total of 21 brokers. This means that the consensus of the 21 different brokers is leaning toward to buy/moderate buy.
Sell
1 (4.76%) Underweight
1 (4.76%) Hold
3 (14.29%) Overweight
2 (9.52%) Buy
14 (66.67%)
Price target by analysts
The 16 latest analyst estimates, per Thursday 22 October, 2020, show the following high, low and average price targets.
Target Average: 119.56 USD
Target High: 130 USD
Target Low: 99 USD
Latest News: Plausible Report on Cholesterol Medicines Market 2020-2027| Abbott Laboratories, Merck& Co, Bristol-Myers Squibb Company, AstraZeneca
Sunday, 25 October 2020, 15:26:54
To provide the global outlook of the Cholesterol Medicines Market a new statistical study has added by HealthCare Intelligence Markets to its massive database. During the analysis of this market the existing industries, as well as upcoming start-ups, have been
— OpenPR
Credit Suisse Group Lowers Abbott Laboratories (NYSE:ABT) Price Target to $118.00
Sunday, 25 October 2020, 10:10:47
Abbott Laboratories (NYSE:ABT) had its price target trimmed by Credit Suisse Group from $136.00 to $118.00 in a research report report published on Thursday, The Fly reports. The firm currently has an outperform rating on the healthcare product maker’s stock. A number of other research analysts also recently weighed in on the company. JPMorgan Chase […]
— Zolmax News
Abbott Laboratories (NYSE:ABT) Price Target Raised to $114.00
Sunday, 25 October 2020, 10:10:47
Abbott Laboratories (NYSE:ABT) had its price target boosted by Raymond James from $102.00 to $114.00 in a research note issued to investors on Thursday, Anlyst Ratings reports. The brokerage currently has an outperform rating on the healthcare product maker’s stock. Other research analysts have also recently issued research reports about the stock. Bank of America […]
— Zolmax News
Raymond James Increases Abbott Laboratories (NYSE:ABT) Price Target to $114.00
Sunday, 25 October 2020, 10:10:46
Abbott Laboratories (NYSE:ABT) had its target price boosted by Raymond James from $102.00 to $114.00 in a report published on Thursday, Anlyst Ratings reports. The firm currently has an outperform rating on the healthcare product maker’s stock. Other equities analysts also recently issued research reports about the stock. SVB Leerink upped their price objective on […]
— Dakota Financial News
Abbott Laboratories (NYSE:ABT) Expected to Post FY2020 Earnings of $3.55 Per Share
Sunday, 25 October 2020, 03:12:44
Abbott Laboratories (NYSE:ABT) – Investment analysts at William Blair raised their FY2020 earnings estimates for shares of Abbott Laboratories in a research report issued on Wednesday, October 21st. William Blair analyst M. Kaczor now anticipates that the healthcare product maker will post earnings per share of $3.55 for the year, up from their previous estimate […]
— Stock Observer
We recommend that you check out Capital.com as they have a very good selection of stocks available for both going short and long.
